CCI4EU - Cost of health care and drugs

MATERIALS AVAILABLE

CCI4EU - Cost of health care and drugs

MATERIALS AVAILABLE


Chairs

: Mark Lawler, UK & Wim van Harten, NL

Introduction
CCI4EU (Comprehensive Cancer Infrastructures for the European Union) is a European project aiming to help Member States and Associated Countries improve or develop their existing or future Comprehensive Cancer Infrastructures (CCIs), by helping develop their research & innovation-related capacities.
 
This course is the fourth of 10 online training courses organised within the project to help countries develop an effective comprehensive infrastructure and widen the reach of this grant. The topic of this online course is: Cost of health care and drugs.
 
The aim is discuss the economic burden and the economic dividends of cancer.
 
Target audience
Directors, managers and coordinators at hospitals/clinics/CCIs, clinicians, researchers, patients advocates.
 
Course delivery
The first part of this course was made available on this website from 3 February 2025.  
The second part of this online course was held live on 28 February 2025 via this webpage. The entire course was recorded and is now available as on-demand material.

To access the on-demand materials (after the live streaming), participants must register to the course, login to the e-ESO platform and click on the play buttons inside the course programme. 

 
Official language
The course was held in English. Translations are not provided, but English subtitles can be activated and transcriptions can be automatically translated using free online tools.
 
Registration
Registration to the course is free but mandatory. 
 
Certificate of attendance
Participants will be issued a certificate of attendance once they have completed a minimum attendance of 75% of the entire course. An online evaluation questionnaire must be completed in order to receive the certificate that will be issued by email. The evaluation questionnaire will appear in the right-hand column of the course page when participants have completed 75% of the course.
 
Organising secretariat
Sarah Jennie Goldman: sgoldman@eso.net
Francesca Marangoni: fmarangoni@eso.net
Sonia Bulgarelli: sbulgarelli@eso.net
03/02/2025

Introduction to the pre-recorded part of the course

Mark Lawler (UK) Wim H. Van Harten (NL)

03/02/2025

Cost of drugs and negotiation with pharma

The economic burden of cancer

Mark Lawler (UK)

Cost of Cancers (UK)

Katie Spencer (UK)

Cost of Cancer Medicines across EU

Nora Franzen (NL)

Health Technology Assessment alongside the translation research process (VR)

Valesca Retel (NL)

How can we measure the clinical performance and value of drugs after adoption?

Peter S Hall (UK)

03/02/2025

Financial toxicity

Financial toxicity (use of measurement instruments)

Rachel Eckford (DE)

Socio-economic outcomes of Adolecent and Young Adult (AYA) cancer patients

Silvie Janssen (NL)

03/02/2025

The cost of diagnostics

Costs, budget impact and/or cost effectiveness of sequencing

Astrid Kramer (NL)

Cost of testing vs cost of not testing

Peter Keeling (UK)

Health economics and diagnostics/precision medicine

Raymond Henderson (UK)

Costs and cost effectiveness of early detection in head and neck cancer

Lionel Perrier (FR)

03/02/2025

Regulatory part

How countries decide via agencies on coverage

Martina Garau (UK)

How innovation gets to the patients

Wim H. Van Harten (NL)

Coverage with evidence development programs

Joost Verbeek (NL)
28/02/2025 13:00

LIVE STREAMING


28/02/2025 13:00

Introduction & Welcome to the live course

Mark Lawler (UK) Wim H. Van Harten (NL)

28/02/2025 13:05

Live Presentations & Discussions (part 1)

13:05

Comparative overview of costs and infrastructure for cancer treatement in (especially EU) OECD countries

Caroline Berchet (FR)
13:20

Value based health care and use of PROMs in the clinic

Rita Silva Calisto (PT)
13:35

Financial Sustainability

Ajay Aggarwal (UK)
13:50

Discussion


28/02/2025 14:05

Live Presentations & Discussions (part 2)

14:05

Financial Toxicity: Socio-economic impact

Wim H. Van Harten (NL)
14:10

Personal Story Advocate

Marianne Massart (LU)
14:25

Right to be Forgotten

Mark Lawler (UK) Francoise Meunier (BE)
14:45

Discussion


28/02/2025 15:00

Live Cases & Discussions

15:00

Deploying data to influence cancer policy

Mark Lawler (UK)
15:15

Roundtable and Discussion

15:30

Diagnostics case

Valesca Retel (NL)
15:45

Roundtable and discussion


28/02/2025 16:00

Take home message and closing remarks

Mark Lawler (UK) Wim H. Van Harten (NL)

28/02/2025 16:05

End of the course

Ajay Aggarwal profile photo
Ajay Aggarwal

London School of Hygiene and Tropical Medicine, Department of Health Services Research and Policy, London, UK

Astrid Kramer profile photo
Astrid Kramer

, , ,

Caroline Berchet profile photo
Caroline Berchet

Organization for Economic Co-operation and Development (OECD), Healh Policy, Paris Cedex 16, FR

Francoise Meunier profile photo
Francoise Meunier

1050 brussels, BE

Joost Verbeek profile photo
Joost Verbeek

, , ,

Katie Spencer profile photo
Katie Spencer

, , ,

Lionel Perrier profile photo
Lionel Perrier

, , ,

Marianne Massart profile photo
Marianne Massart

, , ,

Mark Lawler profile photo
Mark Lawler

Queens University Hospital, Centre for Cancer Research and Cell Biology, Belfast, UK

Martina Garau profile photo
Martina Garau

, , ,

Nora Franzen profile photo
Nora Franzen

, , ,

Peter Keeling profile photo
Peter Keeling

, , ,

Peter S Hall profile photo
Peter S Hall

, , ,

Rachel Eckford profile photo
Rachel Eckford

German Cancer Research Center (DKFZ), Foundation under Public Law, Heidelberg, DE

Raymond Henderson profile photo
Raymond Henderson

, , ,

Rita Silva Calisto profile photo
Rita Silva Calisto

Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E., ORLab, Porto, PT

Silvie Janssen profile photo
Silvie Janssen

, , ,

Valesca Retel profile photo
Valesca Retel

, , ,

Wim H. Van Harten profile photo
Wim H. Van Harten

Rijnstate Ziekenhuis, Chairman Board of Directors, Arnhem, NL